• Immunogenicity Assessment

    • Therapeutic In Silico Services
      • ISPRIâ„¢ Website
      • ISPRI Downselectâ„¢
      • ISPRI Quantifyâ„¢
      • ISPRI Analyzeâ„¢
      • ISPRI Evaluateâ„¢
      • ISPRI-HCPâ„¢
      • ISPRI Designâ„¢
      • PANDA® Screening
    • Vaccine In Silico Services
      • iVAXâ„¢
      • EpiCCâ„¢
      • Ancer®
      • PreVAXâ„¢
    • Lab Services
      • All In Vitro Assays
      • Generic Peptide PANDA® Assays
    • Consulting Services
      • Trusted Expert Advice (TEA)
      • IRA / ISI Regulatory Writing Support
    • Why Immunogenicity Risk Assessment?
    • Why EpiVax?
  • About Us
    • Company History
    • Leadership
    • Careers
  • Press
    • News
    • Events
    • Publications
    • Blog
  • Contact Us
Poster: In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

Poster: In silico Immunogenicity Assessment for Sequences Containing Unnatural Amino Acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Mar 14, 2023

Poster: Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

Poster: Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides

by Elena Iemma | Mar 14, 2023

Promiscuous T Cell Binding Epitopes in Two Osteoporosis Medications Lead to Different Immunogenicity Profiles: A Tale of Two Peptides  
Poster: Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

Poster: Tumor homology with self as a biomarker for response to checkpoint inhibitor therapy

by Elena Iemma | Nov 17, 2022

EpiVaxTx_SITC22_Melanoma_28Oct22_56Wx31.5H    
In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

In silico immunogenicity assessment for sequences containing unnatural amino acids: A method using existing in silico algorithm infrastructure and a vision for future enhancements

by Elena Iemma | Oct 11, 2022

Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases

Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases

by Elena Iemma | Dec 23, 2021

Development of highly stable and de-immunized versions of recombinant alpha interferon: Promising candidates for the treatment of chronic and emerging viral diseases
« Older Entries

Recent Posts

  • EpiVax Announces Laboratory Expansion and Streamlined, NAM-Centric In Vitro Services    
  • Replacing Animal Models with Human-Relevant New Approach Methodologies (NAMs) for Immunogenicity in Clinic
  • EpiVax Enters its Next Chapter with SV Health Investors
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy
  • Immunogenicity Risk Assessment Outputs to Drive a Streamlined, Risk-Based Preclinical and Clinical Strategy

Recent Comments

No comments to show.

Explore

Therapeutic In Silico Services

Vaccine In Silico Services

Lab Services

Consulting

LinkedIn

About Us

Careers

News

Events

Publications

Contact Us

This website uses cookies and similar technologies to collect information about your website experience for advertising, analytics, and other purposes as described in our Privacy Policy.